BR9812127A - Arylpyridazinones as inhibitors of prostaglein biosynthesis endoperoxide h synthase - Google Patents
Arylpyridazinones as inhibitors of prostaglein biosynthesis endoperoxide h synthaseInfo
- Publication number
- BR9812127A BR9812127A BR9812127-8A BR9812127A BR9812127A BR 9812127 A BR9812127 A BR 9812127A BR 9812127 A BR9812127 A BR 9812127A BR 9812127 A BR9812127 A BR 9812127A
- Authority
- BR
- Brazil
- Prior art keywords
- cox
- inhibitors
- prostaglein
- endoperoxide
- cyclooxygenase
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D237/14—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D237/18—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Abstract
"ARILPIRIDAZINONAS COMO INIBIDORES DA BIOSSìNTESE DE PROSTAGLEINA ENDOPERóXIDO H SINTASE" A presente invenção divulga compostos de piridazinona, os quais são inibidores da ciclooxigenase (COX) e, em particular, são inibidores seletivos da ciclooxigenase-2 (COX/2). A COX-2 é a isoforma capaz de ser induzida associada com a inflamação, em oposição à isoforma constitutiva, a ciclooxigenase-1 (COX-1), que é uma enzima "zeladora" importante em muitos tecidos, incluindo o trato gastrointestinal (GI) e os rins. A seletividade destes compostos para a COX-2 minimiza os efeitos colaterais GI e renais não desejados, vistos com as drogas antiinflamatórias não-esteroidais (NSAIDs) atualmente vendidas."ARYLYPYRIDAZINES AS INHIBITORS OF PROSTAGLEIN ENDOPEROXIDE H SYNTHESIS BIOSYNTHESIS" The present invention discloses pyridazinone compounds, which are inhibitors of cyclooxygenase (COX) and, in particular, are selective inhibitors of cyclooxygenase-2 (COX / 2). COX-2 is the isoform capable of being induced associated with inflammation, as opposed to the constitutive isoform, cyclooxygenase-1 (COX-1), which is an important "janitor" enzyme in many tissues, including the gastrointestinal tract (GI ) and the kidneys. The selectivity of these compounds for COX-2 minimizes unwanted GI and renal side effects, seen with the currently sold non-steroidal anti-inflammatory drugs (NSAIDs).
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US91702397A | 1997-08-22 | 1997-08-22 | |
PCT/US1998/016479 WO1999010331A1 (en) | 1997-08-22 | 1998-08-10 | Arylpyridazinones as prostaglandin endoperoxide h synthase biosynthesis inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
BR9812127A true BR9812127A (en) | 2000-07-18 |
Family
ID=25438243
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR9812127-8A BR9812127A (en) | 1997-08-22 | 1998-08-10 | Arylpyridazinones as inhibitors of prostaglein biosynthesis endoperoxide h synthase |
Country Status (8)
Country | Link |
---|---|
EP (1) | EP1007515A1 (en) |
BR (1) | BR9812127A (en) |
CA (1) | CA2299300C (en) |
CO (1) | CO4970740A1 (en) |
SA (1) | SA98190764B1 (en) |
TW (1) | TWI232216B (en) |
WO (1) | WO1999010331A1 (en) |
ZA (1) | ZA987555B (en) |
Families Citing this family (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6307047B1 (en) * | 1997-08-22 | 2001-10-23 | Abbott Laboratories | Prostaglandin endoperoxide H synthase biosynthesis inhibitors |
US6525053B1 (en) * | 1997-08-22 | 2003-02-25 | Abbott Laboratories | Prostaglandin endoperoxide H synthase biosynthesis inhibitors |
WO1999025697A1 (en) | 1997-11-19 | 1999-05-27 | Kowa Co., Ltd. | Novel pyridazine derivatives and drugs containing the same as the active ingredient |
TWI241295B (en) | 1998-03-02 | 2005-10-11 | Kowa Co | Pyridazine derivative and medicine containing the same as effect component |
AU756275B2 (en) | 1998-08-14 | 2003-01-09 | Nihon Nohyaku Co., Ltd. | Pyridazinone derivatives |
BR9914858A (en) * | 1998-10-27 | 2002-02-05 | Abbott Lab | Prostaglandin endoperoxide biosynthesis inhibitors h |
US6833373B1 (en) | 1998-12-23 | 2004-12-21 | G.D. Searle & Co. | Method of using an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia |
JP2000247959A (en) | 1999-02-26 | 2000-09-12 | Kowa Co | Pyridazin-3-one derivative, and drug containing the same |
AP2002002582A0 (en) | 1999-12-23 | 2002-09-30 | Nitromed Inc | Nitrosated and nitrosylated cyclooxygenase-2 inhibitors, compositions and methods of use |
US6664256B1 (en) | 2000-07-10 | 2003-12-16 | Kowa Co., Ltd. | Phenylpyridazine compounds and medicines containing the same |
ITMI20010733A1 (en) | 2001-04-05 | 2002-10-05 | Recordati Chem Pharm | USE OF ISOENZIN COX-2 INHIBITORS FOR THE TREATMENT OF URINARY INCONTINENCE |
WO2003059891A1 (en) * | 2002-01-18 | 2003-07-24 | Pharmacia Corporation | Substituted pyridazinones as inhibitors of p38 |
WO2004083188A1 (en) | 2003-03-18 | 2004-09-30 | Kowa Co., Ltd. | Water-soluble phenylpyridazine derivative and medicine containing the same |
DK1534305T3 (en) | 2003-05-07 | 2007-02-05 | Osteologix As | Treatment of cartilage / bone disorders with water-soluble strontium salts |
WO2005007632A1 (en) * | 2003-07-18 | 2005-01-27 | Pharmacia Corporation | Substituted pyridazinones as inhibitors of p38 |
EP1767529B1 (en) | 2004-06-09 | 2009-05-06 | Sumitomo Chemical Company, Limited | Pyridazine compound and use thereof |
US7795258B2 (en) | 2004-06-28 | 2010-09-14 | Sumitomo Chemical Company, Limited | Pyridazine compound and use thereof |
US7728013B2 (en) | 2005-05-10 | 2010-06-01 | Intermune, Inc. | Method of modulating stress-activated protein kinase system |
EP1932840B1 (en) * | 2005-10-03 | 2014-04-09 | Ono Pharmaceutical Co., Ltd. | Nitrogen-containing heterocyclic compound and pharmaceutical application thereof |
KR20080081914A (en) | 2005-12-07 | 2008-09-10 | 스미또모 가가꾸 가부시끼가이샤 | Pyridazine compound and use thereof |
WO2007080720A1 (en) | 2005-12-07 | 2007-07-19 | Sumitomo Chemical Company, Limited | Pyridazine compound and use thereof |
DE102007008839A1 (en) | 2007-02-23 | 2008-08-28 | Bayer Healthcare Ag | Process for the preparation of 4- (3-hydroxy-3-methylbutoxy) -5- [4- (methylsulfonyl) phenyl] -2-arylpyridazine-3 (2H) -ones |
DE102007008843A1 (en) | 2007-02-23 | 2008-08-28 | Bayer Healthcare Ag | Process for the preparation of 4,5-dihalo-2-aryl-2H-pyridazin-3-ones |
DE102007008840A1 (en) * | 2007-02-23 | 2008-08-28 | Bayer Healthcare Ag | Novel polymorphic form of 2- (4-fluorophenyl) -4-3-hydroxy-3-methyl-1-butoxy) -5- [4-methylsulphonyl) phenyl] -3 (2H) -pyridazinone (FHMP) |
DE102007020689A1 (en) | 2007-05-03 | 2008-11-06 | Bayer Healthcare Ag | Novel polymorphic form of 2- (4-fluorophenyl) -4-3-hydroxy-3-methyl-1-butoxy-5- [4-methylsulfonyl) phenyl] 3 / 2H) -pyridazinone (FHMP) |
DE102007020690A1 (en) * | 2007-05-03 | 2008-11-06 | Bayer Healthcare Ag | New amorphous form of 2- (4-fluorophenyl) -4-3-hydroxy-3-methyl-1-butoxy) -6 [4-methylsulfonyl) phenyl] -3 (2H) -pyridazinone (FHMP) |
EP2296653B1 (en) | 2008-06-03 | 2016-01-27 | Intermune, Inc. | Compounds and methods for treating inflammatory and fibrotic disorders |
JO3115B1 (en) | 2011-08-22 | 2017-09-20 | Takeda Pharmaceuticals Co | Pyridazinone Compounds and Their Use as DAAO Inhibitors |
PE20141361A1 (en) | 2011-11-15 | 2014-10-13 | Takeda Pharmaceutical | AROMATIC DIHYDROXY HETEROCYCLIC COMPOUND |
AR092742A1 (en) | 2012-10-02 | 2015-04-29 | Intermune Inc | ANTIFIBROTIC PYRIDINONES |
CA2943363A1 (en) | 2014-04-02 | 2015-10-08 | Intermune, Inc. | Anti-fibrotic pyridinones |
WO2022195579A1 (en) | 2021-03-15 | 2022-09-22 | Saul Yedgar | Hyaluronic acid-conjugated dipalmitoyl phosphatidyl ethanolamine in combination with non-steroidal anti-inflammatory drugs (nsaids) for treating or alleviating inflammatory diseases |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1988009675A1 (en) * | 1987-06-05 | 1988-12-15 | Medicis Corporation | Inhibition of arachidonic acid metabolism |
AU691673B2 (en) * | 1994-11-14 | 1998-05-21 | Dow Agrosciences Llc | Pyridazinones and their use as fungicides |
US5622948A (en) * | 1994-12-01 | 1997-04-22 | Syntex (U.S.A.) Inc. | Pyrrole pyridazine and pyridazinone anti-inflammatory agents |
-
1998
- 1998-08-10 WO PCT/US1998/016479 patent/WO1999010331A1/en active Application Filing
- 1998-08-10 EP EP98938451A patent/EP1007515A1/en not_active Withdrawn
- 1998-08-10 CA CA002299300A patent/CA2299300C/en not_active Expired - Fee Related
- 1998-08-10 BR BR9812127-8A patent/BR9812127A/en not_active Application Discontinuation
- 1998-08-20 ZA ZA987555A patent/ZA987555B/en unknown
- 1998-08-20 CO CO98047584A patent/CO4970740A1/en unknown
- 1998-09-10 TW TW087113837A patent/TWI232216B/en not_active IP Right Cessation
- 1998-11-16 SA SA98190764A patent/SA98190764B1/en unknown
Also Published As
Publication number | Publication date |
---|---|
SA98190764B1 (en) | 2006-08-06 |
CA2299300C (en) | 2007-04-17 |
WO1999010331A1 (en) | 1999-03-04 |
TWI232216B (en) | 2005-05-11 |
ZA987555B (en) | 1999-02-23 |
CO4970740A1 (en) | 2000-11-07 |
CA2299300A1 (en) | 1999-03-04 |
EP1007515A1 (en) | 2000-06-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR9812127A (en) | Arylpyridazinones as inhibitors of prostaglein biosynthesis endoperoxide h synthase | |
BR9914858A (en) | Prostaglandin endoperoxide biosynthesis inhibitors h | |
CY1105027T1 (en) | INHIBITORS OF ENDOPEROXIDE OR PROSTAGLANDIN BIOSYNTHESIS | |
Janke et al. | Metabolism and epigenetics | |
Hubbard et al. | Evidence for a common mechanism of SIRT1 regulation by allosteric activators | |
Whelton et al. | Renal effects of ibuprofen, piroxicam, and sulindac in patients with asymptomatic renal failure: a prospective, randomized, crossover comparison | |
Lolli et al. | A new class of ibuprofen derivatives with reduced gastrotoxicity | |
Grishanova et al. | Aryl hydrocarbon receptor in oxidative stress as a double agent and its biological and therapeutic significance | |
BRPI0011172B8 (en) | 4,5-diaryl-3(2h)-furanone derivatives as cyclooxygenase-2 inhibitors | |
Chen et al. | Discovery of dual target inhibitors against cyclooxygenases and leukotriene A4 hydrolyase | |
Brunell et al. | Studies on the metabolism and biological activity of the epimers of sulindac | |
Wu et al. | Histone deacetylase 6 (HDAC6) deacetylates extracellular signal-regulated kinase 1 (ERK1) and thereby stimulates ERK1 activity | |
Ramalho et al. | The search for new COX-2 inhibitors: a review of 2002–2008 patents | |
Uddin et al. | Trifluoromethyl fluorocoxib a detects cyclooxygenase-2 expression in inflammatory tissues and human tumor xenografts | |
Petrovic et al. | Using N, N, N’, N’-tetramethyl-p-phenylenediamine (TMPD) to assay cyclooxygenase activity in vitro | |
Huguenin et al. | Evaluation of the antitumoral potential of different nitric oxide-donating non-steroidal anti-inflammatory drugs (NO-NSAIDs) on human urological tumor cell lines | |
Gao et al. | NO-donating aspirin induces phase II enzymes in vitro and in vivo | |
Bhat et al. | Novel sulindac derivatives: Synthesis, characterisation, evaluation of antioxidant, analgesic, anti-inflammatory, ulcerogenic and COX-2 inhibition activity | |
Osmaniye et al. | Design, synthesis and biological evaluation of new N‐acyl hydrazones with a methyl sulfonyl moiety as selective COX‐2 inhibitors | |
Theoduloz et al. | Inhibition of key enzymes in the inflammatory pathway by hybrid molecules of terpenes and synthetic drugs: In vitro and in silico studies | |
Engelhardt et al. | Biological activity of the main metabolites of meloxicam. | |
TR200000478T2 (en) | Arylpyridazinones as inhibitors of prostaglandin endoperoxide H synthase biosynthesis. | |
Tavares | The effects of meloxicam, indomethacin or NS‐398 on eicosanoid synthesis by fresh human gastric mucosa | |
Dammann | Preferential COX-2 inhibition: its clinical relevance for gastrointestinal non-steroidal anti-inflammatory rheumatic drug toxicity | |
Licciardello et al. | Targeting histone methylation: the development of selective methyltransferase and demethylase inhibitors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B09B | Patent application refused [chapter 9.2 patent gazette] |
Free format text: INDEFERIMENTO DO PRESENTE PEDIDO, UMA VEZ QUE DIANTE DO QUE FOI EXPOSTO, OPINO POR NAO ACOLHER A PRESENTACAO DO INTERESSADO E, CONSIDERANDO QUE NAO FORAM APRESENTADOS ARGUMENTOS PERTINENTES, CONCLUI- SE QUE O PEDIDO EM LIDE NAO APRESENTA REQUISITOS QUE JUSTIFIQUEM O SEU REEXAME |
|
B12B | Appeal against refusal [chapter 12.2 patent gazette] |